Author:
Wang Huan,Fu Ziyi,Dai Chencheng,Cao Jian,Liu Xiaoguang,Xu Juan,Lv Mingming,Gu Yun,Zhang Jingmin,Hua Xiangdong,Jia Genmei,Xu Sujuan,Jia Xuemei,Xu Pengfei
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Lukanova, A. & Kaaks, R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 14, 98–107 (2005).
2. Oza, A. M. et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. The Lancet. Oncology 16, 928–936, doi: 10.1016/S1470-2045(15)00086-8 (2015).
3. Prat, J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 460, 237–249, doi: 10.1007/s00428-012-1203-5 (2012).
4. Rustin, G., van der Burg, M., Griffin, C., Qian, W. & Swart, A. M. Early versus delayed treatment of relapsed ovarian cancer. Lancet 377, 380–381, doi: 10.1016/S0140-6736(11)60126-8 (2011).
5. Schuijer, M. & Berns, E. M. TP53 and ovarian cancer. Hum Mutat 21, 285–291, doi: 10.1002/humu.10181 (2003).
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献